JY 102
Alternative Names: JY-102Latest Information Update: 01 Dec 2022
At a glance
- Originator Shenzhen Enduring Biotech
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Polyethylene glycols; Recombinant fusion proteins
- Mechanism of Action CD47 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 17 Nov 2021 Shenzhen Enduring Biotech files for patent protection for JV 108 worldwide
- 20 Jul 2021 Shenzhen Enduring Biotech has patent protection for its core technology platform in USA (Shenzhen Enduring Biotech website; November 2022).
- 10 Apr 2021 Preclinical trials in Solid tumours in China (Parenteral) prior to April 2021